|
1
|
Suzuki R, Takeuchi K, Ohshima K and
Nakamura S: Extranodal NK/T-cell lymphoma: diagnosis and treatment
cues. Hematol Oncol. 26:66–72. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oshimi K: Progress in understanding and
managing natural killer-cell malignancies. Br J Haematol.
139:532–544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liang Q, Ye ZY, Su ZL, et al:
Clinicopathologic study of 963 cases of mature T-cell and natural
killer/T-cell lymphoma with respect to 2008 WHO classification of
lymphoid neoplasms. Chin J Pathol. 39:291–295. 2010.(In
Chinese).
|
|
4
|
Li YX, Wang H, Jin J, et al: Radiotherapy
alone with curative intent in patients with stage I extranodal
nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys.
82:1809–1815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li YX, Yao B, Jin J, Wang WH, et al:
Radiotherapy as primary treatment for stage IE and IIE nasal
natural killer/T-cell lymphoma. J Clin Oncol. 24:181–189. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Isobe K, Uno T, Tamaru J, et al:
Extranodal natural killer/T-cell lymphoma, nasal type: the
significance of radiotherapeutic parameters. Cancer. 106:609–615.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koom WS, Chung EJ, Yang WI, et al:
Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic
viewpoints. Int J Radiat Oncol Biol Phys. 59:1127–1137. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang B, Li XQ, Ma X, Hong X, Lu H and Guo
Y: Immunohistochemical expression and clinical significance of
P-glycoprotein in previously untreated extranodal NK/T-cell
lymphoma, nasal type. Am J Hematol. 83:795–799. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drénou B, Lamy T, Amiot L, et al:
CD3− CD56+ non-Hodgkin’s lymphomas with an
aggressive behavior related to multidrug resistance. Blood.
89:2966–2974. 1997.
|
|
10
|
Jaccard A, Petit B, Girault S, et al:
L-asparaginase-based treatment of 15 western patients with
extranodal NK/T-cell lymphoma and leukemia and a review of the
literature. Ann Oncol. 20:110–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Obama K, Tara M and Niina K:
L-asparaginase-based induction therapy for advanced extranodal
NK/T-cell lymphoma. Int J Hematol. 78:248–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagafuji K, Fujisaki T, Arima F and
Ohshima K: L-asparaginase induced durable remission of relapsed
nasal NK/T-cell lymphoma after autologous peripheral blood stem
cell transplantation. Int J Hematol. 74:447–450. 2001. View Article : Google Scholar
|
|
13
|
Yong W, Zheng W, Zhu J, et al:
L-asparaginase in the treatment of refractory and relapsed
extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 88:647–652.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ahn HK, Kim SJ, Hwang DW, Ko YH, Tang T,
Lim ST and Kim WS: Gemcitabine alone and/or containing chemotherapy
is efficient in refractory or relapsed NK/T-cell lymphoma. Invest
New Drugs. 31:469–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mounier N, El Gnaoui T, Tilly H, et al:
Rituximab plus gemcitabine and oxaliplatin in patients with
refractory/relapsed diffuse large B-cell lymphoma who are not
candidates for high-dose therapy. A phase II Lymphoma Study
Association trial. Haematologica. 98:1726–1731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
López A, Gutiérrez A, Palacios A, et al:
GEMOX-R regimen is a highly effective salvage regimen in patients
with refractory/relapsing diffuse large-cell lymphoma: a phase II
study. Eur J Haematol. 80:127–132. 2008.PubMed/NCBI
|
|
17
|
El Gnaoui T, Dupuis J, Belhadj K, et al:
Rituximab, gemcitabine and oxaliplatin: an effective salvage
regimen for patients with relapsed or refractory B-cell lymphoma
not candidates for high-dose therapy. Ann Oncol. 18:1363–1368.
2007.PubMed/NCBI
|
|
18
|
Nowak-Göttl U, Ahlke E, Fleischhack G, et
al: Thromboembolic events in children with acute lymphoblastic
leukemia (BFM protocols): prednisone versus dexamethasone
administration. Blood. 101:2529–2533. 2003.
|
|
19
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the Committee on Hodgkin’s
Disease Staging Classification. Cancer Res. 31:1860–1861. 1971.
|
|
20
|
Cheson BD, Horning SJ, Coiffier B, et al:
Report of an international workshop to standardize response
criteria for non-Hodgkin’s lymphomas. NCI Sponsored International
Working Group. J Clin Oncol. 17:12441999.PubMed/NCBI
|
|
21
|
Trotti A, Colevas AD, Setser A, et al:
CTCAE v3.0: development of a comprehensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Au WY, Weisenburger DD, Intragumtornchai
T, et al; International Peripheral T-Cell Lymphoma Project.
Clinical differences between nasal and extranasal natural
killer/T-cell lymphoma: a study of 136 cases from the International
Peripheral T-Cell Lymphoma Project. Blood. 113:3931–3937. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yong W, Zheng W and Zhang Y: Clinical
characteristics and treatment of midline nasal and nasal type NK/T
cell lymphoma. Zhonghua Yi Xue Za Zhi. 81:773–775. 2001.(In
Chinese).
|
|
24
|
Lin N, Song Y, Zheng W, et al: A
prospective phase II study of L-asparaginase- CHOP plus radiation
in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J
Hematol Oncol. 6:442013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Au WY, Lie AK, Liang R, et al: Autologous
stem cell transplantation for nasal NK/T-cell lymphoma: a progress
report on its value. Ann Oncol. 14:1673–1676. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim HJ, Bang SM, Lee J, et al: High-dose
chemotherapy with autologous stem cell transplantation in
extranodal NK/T-cell lymphoma: a retrospective comparison with
non-transplantation cases. Bone Marrow Transplant. 37:819–824.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamaguchi M, Kwong YL, Kim WS, et al:
Phase II study of SMILE chemotherapy for newly diagnosed stage IV,
relapsed, or refractory extranodal natural killer (NK)/T-cell
lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin
Oncol. 29:4410–4416. 2011. View Article : Google Scholar
|
|
28
|
Wu X, Li P, Zhao J, et al: A clinical
study of 115 patients with extranodal natural killer/T-cell
lymphoma, nasal type. Clin Oncol (R Coll Radiol). 20:619–625. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li YX, Fang H, Liu QF, et al: Clinical
features and treatment outcome of nasal-type NK/T-cell lymphoma of
Waldeyer ring. Blood. 112:3057–3064. 2008. View Article : Google Scholar : PubMed/NCBI
|
